Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity

A model for intracellular glycosylation in diabetes

Ida Giardino, Diane Edelstein, Michael Brownlee

Research output: Contribution to journalArticle

301 Citations (Scopus)

Abstract

Intracellular sugars are more reactive glycosylating agents than glucose. In vitro nonenzymatic glycosylation of basic fibroblast growth factor (bFGF) by fructose, glucose-6-phosphate (G6P), or glyceraldehyde-3-phosphate (G3P) reduced high affinity heparin-binding activity of recombinant bFGF by 73, 77, and 89%, respectively. Mitogenic activity was reduced 40, 50, and 90%. To investigate the effects of bFGF glycosylation in GM7373 endothelial cells, we first demonstrated that GLUT-1 transporters were not downregulated by increased glucose concentration. In 30 mM glucose, the rate of glucose transport increased 11.6-fold, and the intracellular glucose concentration increased sixfold at 24 h and fivefold at 168 h. The level of total cytosolic protein modified by advanced glycosylation endproducts (AGEs) was increased 13.8-fold at 168 h. Under these conditions, mitogenic activity of endothelial cell cytosol was reduced 70%. Anti-bFGF antibody completely neutralized the mitogenic activity at both 5 and 30 mM glucose, demonstrating that all the mitogenic activity was due to bFGF. Immunoblotting and ELISA showed that 30 mM glucose did not decrease detectable bFGF protein, suggesting that the marked decrease in bFGF mitogenic activity resulted from posttranslational modification of bFGF induced by elevated glucose concentration. Cytosolic AGE-bFGF was increased 6.1-fold at 168 h. These data are consistent with the hypothesis that nonenzymatic glycosylation of intracellular protein alters vascular cell function.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalJournal of Clinical Investigation
Volume94
Issue number1
StatePublished - Jul 1994

Fingerprint

Fibroblast Growth Factor 2
Glycosylation
Endothelial Cells
Glucose
Glyceraldehyde 3-Phosphate
In Vitro Techniques
Glucose-6-Phosphate
Post Translational Protein Processing
Immunoblotting
Cytosol
Blood Vessels
Heparin
Proteins
Down-Regulation
Enzyme-Linked Immunosorbent Assay
Antibodies

Keywords

  • Advanced glycosylation end products
  • Cytokines
  • Glucose
  • Heparin
  • Mitogens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity : A model for intracellular glycosylation in diabetes. / Giardino, Ida; Edelstein, Diane; Brownlee, Michael.

In: Journal of Clinical Investigation, Vol. 94, No. 1, 07.1994, p. 110-117.

Research output: Contribution to journalArticle

@article{bcaae5c4879c4867a0297e8ae0f71bde,
title = "Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: A model for intracellular glycosylation in diabetes",
abstract = "Intracellular sugars are more reactive glycosylating agents than glucose. In vitro nonenzymatic glycosylation of basic fibroblast growth factor (bFGF) by fructose, glucose-6-phosphate (G6P), or glyceraldehyde-3-phosphate (G3P) reduced high affinity heparin-binding activity of recombinant bFGF by 73, 77, and 89{\%}, respectively. Mitogenic activity was reduced 40, 50, and 90{\%}. To investigate the effects of bFGF glycosylation in GM7373 endothelial cells, we first demonstrated that GLUT-1 transporters were not downregulated by increased glucose concentration. In 30 mM glucose, the rate of glucose transport increased 11.6-fold, and the intracellular glucose concentration increased sixfold at 24 h and fivefold at 168 h. The level of total cytosolic protein modified by advanced glycosylation endproducts (AGEs) was increased 13.8-fold at 168 h. Under these conditions, mitogenic activity of endothelial cell cytosol was reduced 70{\%}. Anti-bFGF antibody completely neutralized the mitogenic activity at both 5 and 30 mM glucose, demonstrating that all the mitogenic activity was due to bFGF. Immunoblotting and ELISA showed that 30 mM glucose did not decrease detectable bFGF protein, suggesting that the marked decrease in bFGF mitogenic activity resulted from posttranslational modification of bFGF induced by elevated glucose concentration. Cytosolic AGE-bFGF was increased 6.1-fold at 168 h. These data are consistent with the hypothesis that nonenzymatic glycosylation of intracellular protein alters vascular cell function.",
keywords = "Advanced glycosylation end products, Cytokines, Glucose, Heparin, Mitogens",
author = "Ida Giardino and Diane Edelstein and Michael Brownlee",
year = "1994",
month = "7",
language = "English (US)",
volume = "94",
pages = "110--117",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity

T2 - A model for intracellular glycosylation in diabetes

AU - Giardino, Ida

AU - Edelstein, Diane

AU - Brownlee, Michael

PY - 1994/7

Y1 - 1994/7

N2 - Intracellular sugars are more reactive glycosylating agents than glucose. In vitro nonenzymatic glycosylation of basic fibroblast growth factor (bFGF) by fructose, glucose-6-phosphate (G6P), or glyceraldehyde-3-phosphate (G3P) reduced high affinity heparin-binding activity of recombinant bFGF by 73, 77, and 89%, respectively. Mitogenic activity was reduced 40, 50, and 90%. To investigate the effects of bFGF glycosylation in GM7373 endothelial cells, we first demonstrated that GLUT-1 transporters were not downregulated by increased glucose concentration. In 30 mM glucose, the rate of glucose transport increased 11.6-fold, and the intracellular glucose concentration increased sixfold at 24 h and fivefold at 168 h. The level of total cytosolic protein modified by advanced glycosylation endproducts (AGEs) was increased 13.8-fold at 168 h. Under these conditions, mitogenic activity of endothelial cell cytosol was reduced 70%. Anti-bFGF antibody completely neutralized the mitogenic activity at both 5 and 30 mM glucose, demonstrating that all the mitogenic activity was due to bFGF. Immunoblotting and ELISA showed that 30 mM glucose did not decrease detectable bFGF protein, suggesting that the marked decrease in bFGF mitogenic activity resulted from posttranslational modification of bFGF induced by elevated glucose concentration. Cytosolic AGE-bFGF was increased 6.1-fold at 168 h. These data are consistent with the hypothesis that nonenzymatic glycosylation of intracellular protein alters vascular cell function.

AB - Intracellular sugars are more reactive glycosylating agents than glucose. In vitro nonenzymatic glycosylation of basic fibroblast growth factor (bFGF) by fructose, glucose-6-phosphate (G6P), or glyceraldehyde-3-phosphate (G3P) reduced high affinity heparin-binding activity of recombinant bFGF by 73, 77, and 89%, respectively. Mitogenic activity was reduced 40, 50, and 90%. To investigate the effects of bFGF glycosylation in GM7373 endothelial cells, we first demonstrated that GLUT-1 transporters were not downregulated by increased glucose concentration. In 30 mM glucose, the rate of glucose transport increased 11.6-fold, and the intracellular glucose concentration increased sixfold at 24 h and fivefold at 168 h. The level of total cytosolic protein modified by advanced glycosylation endproducts (AGEs) was increased 13.8-fold at 168 h. Under these conditions, mitogenic activity of endothelial cell cytosol was reduced 70%. Anti-bFGF antibody completely neutralized the mitogenic activity at both 5 and 30 mM glucose, demonstrating that all the mitogenic activity was due to bFGF. Immunoblotting and ELISA showed that 30 mM glucose did not decrease detectable bFGF protein, suggesting that the marked decrease in bFGF mitogenic activity resulted from posttranslational modification of bFGF induced by elevated glucose concentration. Cytosolic AGE-bFGF was increased 6.1-fold at 168 h. These data are consistent with the hypothesis that nonenzymatic glycosylation of intracellular protein alters vascular cell function.

KW - Advanced glycosylation end products

KW - Cytokines

KW - Glucose

KW - Heparin

KW - Mitogens

UR - http://www.scopus.com/inward/record.url?scp=0028304845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028304845&partnerID=8YFLogxK

M3 - Article

VL - 94

SP - 110

EP - 117

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -